ABLEDOCS
6.4.2021 14:03:02 CEST | Business Wire | Pressemeddelelse
AbleDocs Inc. , globalt førende udbyder af tilgængelige PDF-produkter og -services, og Diversa Docs ApS , anerkendte eksperter inden for PDF- og Web-tilgængelighedsydelser, annoncerer, at de går sammen for at blive førende i Skandinavien inden for PDF-tilgængelighedsprodukter og -services.
Med en allerede mangeårig historik for samarbejde glæder begge virksomheders grundlæggere og lederteam til at udnytte hinandens muligheder for at tilbyde større fordele til eksisterende og nye kunder.
”Diversa Docs er bredt anerkendt for deres ekspertise inden for levering af PDF/UA-kompatible og tilgængelige PDF-filer, og denne erhvervelse giver vores kombinerede kundebase mulighed for at drage fordel af oplevelsen og omfanget af vores produkter og tjenester i hele Skandinavien,” siger AbleDocs 'Præsident (GLOBAL), Adam Spencer .
”Med deres fantastiske hold og fokuserede tilgang på slutbrugeren er de den ideelle partner for AbleDocs. Med vores samlede indsats kan sammen vi drive udbredelsen af næste generations PDF-tilgængelighedstjenester og -løsninger, ”siger Vice President (SCANDINAVIA), Jens Bjerre Kirkegaard .
”Tilgængelighed har altid appelleret til mig, fordi det kombinerer et teknisk felt med et humanistisk område,” siger administrerende direktør for Diversa Docs, Asbjørn Fangel-Hansen . ”Efter at have arbejdet i 12 år i den danske offentlige sektor inden for tilgængelighed og senest som ejer af en af de førende virksomheder inden for tilgængelighed i Danmark, er jeg meget beæret over at blive en del af en af de absolut førende globale aktører, når det kommer til tilgængelige dokumenter, ”tilføjer Fangel-Hansen.
Kombinationen af AbleDocs og Diversa Docs vil udvide den globale tilstedeværelse af AbleDocs med produkter, services, udvikling af løsninger og uddannelse tilpasset til lokale forhold på 49 sprog for at sikre, at kunderne får de bedst mulige tilbud.
Om Diversa Docs
Diversa Docs ApS blev grundlagt af Lars Holm-Sørensen og Asbjørn Fangel-Hansen i 2019 som søsterselskab til Diversa ApS. Siden da har virksomheden udviklet sig til at være en af de førende i Danmark med hensyn til dokumenttilgængelighed og området generelt.
Om AbleDocs Inc.
AbleDocs blev grundlagt i 2019 som et konglomerat af udbydere af PDF-tilgængelighedstjenester og er vokset til at have aktiviteter i Canada, Danmark, Tyskland, Schweiz og USA. Grundlæggerne har mere end 150 års kombineret erfaring med tilgængelige dokumenter i og har siden udvidet sine tilbud til også at inkludere en helt ny tilgang til dokumenttilgængelighedsstrategier og løsninger til tilgængelige dokument produceret i store mængder samt test af tilgængelige dokumenter.
AbleDocs er det eneste firma i verden, der garanterer, at hver fil, de producerer, overholder gældende lovgivning for tilgængelighed og bakker det op med en garanti på $ 10.000.000.
Aktuelle produkter og services fra AbleDocs inkluderer ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord og axesPDF.
For mere information, besøg https://www.abledocs.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210406005231/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum